BenevolentAI Overview
Company Headquarters: UK, Europe
Founded: 2013
Workforce: 500
Company Working: BenevolentAI is a clinical-stage AI-enabled drug discovery and development company. Through the combined capabilities of its AI platform, scientific expertise, and web-lab facilities, Benevolent AI is well-established to deliver novel drug candidates with a higher probability of clinical success. Moreover, BenevolentAI powers a growing in-house pipeline of 13 named drug programmers, and it maintains collaboration with AstraZeneca (UK), as well as research and charitable institutions. The company offers its services under the category of pipeline, COVID-19, atopic dermatitis, and ulcerative colitis as well as company has a strong market presence in Europe.
Strategy
BenevolentAI focuses on the technological development of AI in drug discovery. The company also strategizes on the development of an AI-enabled drug discovery platform for pharmaceutical solutions. The company also emphasizes the innovation and development of advanced technological solutions which focuses on the application of its technology platform in human health and veterinary medicine.
